Masitinib is under clinical development by AB Science and currently in Phase III for Metastatic Pancreatic Cancer. According to GlobalData, Phase III drugs for Metastatic Pancreatic Cancer have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Masitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Masitinib (AB-1010) is under development for the treatment of severe chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis, systemic mastocytosis, non resectable locally advanced or metastatic pancreatic cancer, gastrointestinal stromal tumor, adenocarcinoma of the gastroesophageal junction, androgen-independent prostate cancer, Alzheimer's disease, asthma, secondary progressive multiple sclerosis, primary progressive multiple sclerosis, ovarian cancer, metastatic epithelial ovarian cancer, primary peritoneal, primary fallopian tube cancer, relapsing-remitting multiple sclerosis, peripheral T-cell lymphomas including adult t-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+), angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma ALK possitive and negative, peripheral T-cell lymphoma, extranodal natural killer (NK)/T-cell lymphoma, enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma, subcutaneous panniculitis T-cell lymphoma and transformed mycosis fungoides. The drug candidate is administered orally. It is an ATP-binding site competitor. The drug candidate acts by inhibiting wild-type forms of c-KIT, Fyn, Lyn tyrosine kinase and platelet-derived growth factor receptor alpha and beta. Masitinib is a selective inhibitor of the tyrosine kinase inhibitor that targets KIT.
It is under development for the treatment of coronavirus disease 2019 (COVID-19), systemic mastocytosis, mast cell activation syndrome (MCAS) and amyotrophic lateral sclerosis.
The drug candidate was under development for the treatment of metastatic colorectal cancer, progressive supranuclear palsy, chronic plaque psoriasis, Parkinson's disease, indolent systemic mastocytosis, metastatic melanoma with and without JM mutation of c-KIT, glioblastoma multiforme, triple-negative breast cancer, metastatic breast cancer, gastric cancer, head and neck cancer, acute ischemic stroke, Dysthymia, depression, metastatic liver cancer, Crohn's disease (regional enteritis), hepatocellular carcinoma, castration resistant prostate cancer, relapsed/refractory multiple myeloma and non-small cell lung cancer and metastatic ovarian cancer as a second line therapy.
AB Science overview
AB Science (ABS) is a pharmaceutical company. It offers protein kinase inhibitors. The company’s lead compound Masitinib, is a orally administered tyrosine kinase inhibitor targeting mast cells and selected kinases, including c-Kit, PDGFR, and Lyn in several human indications such as oncology, inflammatory diseases, and central nervous system diseases. AB Science has developed several medicines for humans, on-going phase 2 and phase 3 studies in oncology and non-oncology diseases. The company is commercializing its lead product candidate in human and veterinary medicine. It has operations in France and the US. ABS is headquartered in Paris, France.
For a complete picture of Masitinib’s drug-specific PTSR and LoA scores, buy the report here.